Medical Care Technologies (OTC Pink:MDCE) Positions Itself in the Multi-Billion Dollar AI Dermatology Market With Google-Backed Melanoma Detection Technology

Rhea-AI Summary

Medical Care Technologies (OTC Pink: MDCE) announced on December 8, 2025 that it has integrated Derm Foundation, a Google-backed pretrained dermatology imaging model, into its soon-to-launch AI wound and skin monitoring mobile platform.

The integration provides melanoma risk classification, chronic-wound progress tracking, data-efficient classification for conditions like psoriasis and dermatitis, automated image-quality checks, and HTTPS API integration for rapid mobile deployment. The company positions the app to enable earlier melanoma detection and reduce preventable hospitalizations by detecting infection risk and wound deterioration from smartphone images.

Company claims note melanoma early-detection survival can reach up to 99% and cite chronic wounds affecting 50 million+ people globally; the app targets rural, underserved and telehealth use cases.

MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce a major technology advancement in the development of its soon-to-launch AI wound and skin monitoring platform. The Company has strategically aligned with Derm Foundation, a Google-backed pretrained dermatology imaging model, enabling the app to rapidly evolve into one of the most accessible early-warning tools for melanoma, infection risks, and chronic wound deterioration directly from a smartphone.

Led by CEO Marshall Perkins, MDCE is building a revolutionary solution empowering users to capture wound and skin images safely at home, while AI analyzes and detects subtle-often early and invisible-signs of disease progression.

"We are deploying one of the world's most advanced dermatology AI models into an easy-to-use mobile platform," said Perkins.
"Our mission is to save lives by enabling earlier melanoma detection and reducing preventable hospitalizations from chronic wounds."

Derm Foundation: A High-Power AI Engine Built for Clinical Skin Detection

Derm Foundation technology provides MDCE with:

• Melanoma risk classification - identifying suspicious lesions and alerting users to potential early skin-cancer indicators

• Progress tracking for chronic wounds - enabling sequential imaging to detect stagnation or infection risks

• Data-efficient skin-disease classification including:

  • Psoriasis

  • Dermatitis

  • Other dermatological conditions aligned with clinical screening

• Automated image quality checks - ensuring photos are suitable for reliable AI analysis

• Full integration for mobile apps via HTTPS "predict" API endpoints

By embedding Derm Foundation, MDCE can rapidly scale world-class AI dermatology capabilities into a consumer-first solution without waiting for traditional multi-year model development.

A Global Need for Early Detection - Delivered at Home

Melanoma is the deadliest form of skin cancer - yet early detection can increase survival rate up to 99%.

Chronic wounds, including diabetic ulcers, impact 50 million+ people globally and contribute to billions in avoidable medical costs each year.

MDCE's app is designed to:

• Detect and flag early melanoma suspicion

• Track wound healing trajectories in real time

• Help prevent infections and amputations

• Empower users in rural and underserved communities

• Support telehealth and caregiver coordination

"Dermatological and wound-care intelligence shouldn't only be available inside a hospital," Perkins added.
"We are democratizing access to some of the most critical early-screening tools in modern medicine."

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC Pink: MDCE) is redefining preventive and remote healthcare through AI-empowered imaging solutions. The Company is advancing clinical-aligned tools that give users and caregivers greater independence, safety, and decision-making power from their mobile devices.

Learn more: www.medicalcaretechnologies.com

Safe Harbor Statement

This press release contains forward-looking statements, including statements related to technology development, product capabilities, clinical potential, market opportunity, and future business performance. These statements involve risks and uncertainties that could cause actual results to differ materially. Medical Care Technologies Inc. assumes no obligation to update any forward-looking statements.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What did Medical Care Technologies (MDCE) announce on December 8, 2025 about Derm Foundation?

MDCE announced it integrated the Google-backed Derm Foundation pretrained dermatology model into its upcoming AI wound and skin monitoring app.

How will MDCE's app use Derm Foundation to detect melanoma and wound issues?

The app will use Derm Foundation for melanoma risk classification, chronic-wound progress tracking, infection-risk alerts, and automated image-quality checks.

Does the MDCE announcement specify regulatory approvals or clinical trial results for the app?

No— the announcement describes technology integration and intended uses but does not cite regulatory approvals or completed clinical trial results.

What clinical benefits does MDCE claim the app may provide for melanoma detection?

MDCE highlights that early melanoma detection can raise survival to up to 99% and that the app aims to flag suspicious lesions for earlier evaluation.

Who are the target users for MDCE's AI wound and skin monitoring platform (MDCE)?

The company targets consumers capturing photos at home, rural and underserved communities, caregivers, and telehealth providers.

How will Derm Foundation be delivered inside MDCE's mobile app?

Derm Foundation will be integrated via HTTPS 'predict' API endpoints to enable in-app image analysis and scaling without multi-year model development.